Eledon Pharmaceuticals Inc (ELDN) Stock Price, Quote & News

Company Profile

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 238 8090

Website: eledon.com

Address:

19800 MacArthur Boulevard, Suite 250, Irvine, United States

DPaul5151 Dec. 4 at 6:41 PM

$ELDN making the turn back north good time to buy

0 · Reply

red1 Dec. 4 at 6:16 PM

$ELDN dump to 1.40sss soon… load up rince repeat

0 · Reply

red1 Dec. 4 at 3:05 PM

$ELDN we’re going to be trading between 1.40-1.60 for a while until BO/partnership rummors start

0 · Reply

Veraton Dec. 4 at 2:23 PM

$ELDN Nothing new Same shit...

0 · Reply

red1 Dec. 3 at 8:36 PM

$ELDN dout it …. Just ETF buying the whole sector is up

0 · Reply

Veraton Dec. 3 at 7:42 PM

$ELDN We are flying tomorrow.. Expecting good info webcast piper sandler

0 · Reply

red1 Dec. 2 at 6:46 PM

$ELDN $VRTX I’m not the only one that this vertex will acquire eledon https://www.facebook.com/share/r/17rqowXx65/

0 · Reply

red1 Dec. 2 at 5:28 PM

$ELDN added

0 · Reply

Sheajones Dec. 1 at 2:37 PM

$ELDN Digest this. There is always crossover when it comes to niche medicine. Whether it's doctors, hospitals, or trials, it is very common for there to be parallels. With that said, it is a far cry from a potential buyout because there are many more important factors that take precedent when it comes to a buyout or merger. And next time Veraton, dont block people that call you out on your BS hoping they wont see your boiler plate sales tactics, be a man. Good try though swindler.

0 · Reply

Veraton Dec. 1 at 1:25 PM

$ELDN piper Sandler meeting = strong investment bankers health are industry 🐂

0 · Reply

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

Nov 18, 2025, 4:05 PM EST - 16 days ago

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Nov 17, 2025, 1:07 PM EST - 17 days ago

Eledon Pharmaceuticals, Inc. (ELDN) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 14, 2025, 5:00 PM EST - 20 days ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 12, 2025, 7:56 AM EST - 22 days ago

Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Nov 11, 2025, 5:26 PM EST - 23 days ago

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Nov 7, 2025, 2:36 PM EST - 27 days ago

Eledon Pharmaceuticals, Inc. (ELDN) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression Transcript

Nov 7, 2025, 1:36 PM EST - 27 days ago

Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study

Nov 6, 2025, 6:30 PM EST - 27 days ago

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting

Nov 5, 2025, 7:00 AM EST - 4 weeks ago

Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference

Oct 17, 2025, 7:00 AM EDT - 6 weeks ago

Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

Sep 24, 2025, 4:05 PM EDT - 2 months ago

Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

Aug 29, 2025, 7:00 AM EDT - 3 months ago

Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

Aug 14, 2025, 4:20 PM EDT - 4 months ago

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

Aug 6, 2025, 4:01 PM EDT - 4 months ago

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Jul 30, 2025, 4:05 PM EDT - 4 months ago

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

Jul 17, 2025, 4:01 PM EDT - 5 months ago

Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

Jun 25, 2025, 4:01 PM EDT - 5 months ago

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

May 14, 2025, 4:01 PM EDT - 7 months ago

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

May 6, 2025, 1:15 PM EDT - 7 months ago

Undercovered Dozen: Gevo, Eledon, Dorian, Iridium +

GEVO IRDM LPG

May 3, 2025, 8:15 AM EDT - 7 months ago

Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet

Mar 20, 2025, 4:01 PM EDT - 9 months ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Mar 4, 2025, 4:05 PM EST - 9 months ago

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Feb 7, 2025, 10:00 AM EST - 10 months ago

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Jan 29, 2025, 4:05 PM EST - 11 months ago

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 28, 2025, 11:27 AM EST - 11 months ago

Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business

Jan 13, 2025, 7:00 AM EST - 11 months ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Nov 12, 2024, 4:01 PM EST - 1 year ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Oct 29, 2024, 3:51 PM EDT - 1 year ago

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29, 2024, 7:46 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Oct 29, 2024, 7:45 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Sep 11, 2024, 4:05 PM EDT - 1 year ago

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Sep 4, 2024, 7:00 AM EDT - 1 year ago

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Aug 14, 2024, 5:21 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Jul 2, 2024, 4:05 PM EDT - 1 year ago

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

May 9, 2024, 7:30 AM EDT - 1 year ago

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

May 9, 2024, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

May 7, 2024, 7:05 AM EDT - 1 year ago

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

Mar 28, 2024, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Mar 25, 2024, 4:56 PM EDT - 1 year ago

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Mar 21, 2024, 10:31 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Feb 13, 2024, 7:01 PM EST - 1 year ago

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 4, 2024, 4:40 PM EST - 2 years ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

Nov 29, 2023, 4:05 PM EST - 2 years ago

Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

Nov 9, 2023, 4:01 PM EST - 2 years ago

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

Nov 8, 2023, 4:05 PM EST - 2 years ago

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

Nov 2, 2023, 9:05 AM EDT - 2 years ago

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

Oct 13, 2023, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting

DPaul5151 Dec. 4 at 6:41 PM

$ELDN making the turn back north good time to buy

0 · Reply

red1 Dec. 4 at 6:16 PM

$ELDN dump to 1.40sss soon… load up rince repeat

0 · Reply

red1 Dec. 4 at 3:05 PM

$ELDN we’re going to be trading between 1.40-1.60 for a while until BO/partnership rummors start

0 · Reply

Veraton Dec. 4 at 2:23 PM

$ELDN Nothing new Same shit...

0 · Reply

red1 Dec. 3 at 8:36 PM

$ELDN dout it …. Just ETF buying the whole sector is up

0 · Reply

Veraton Dec. 3 at 7:42 PM

$ELDN We are flying tomorrow.. Expecting good info webcast piper sandler

0 · Reply

red1 Dec. 2 at 6:46 PM

$ELDN $VRTX I’m not the only one that this vertex will acquire eledon https://www.facebook.com/share/r/17rqowXx65/

0 · Reply

red1 Dec. 2 at 5:28 PM

$ELDN added

0 · Reply

Sheajones Dec. 1 at 2:37 PM

0 · Reply

Veraton Dec. 1 at 1:25 PM

$ELDN piper Sandler meeting = strong investment bankers health are industry 🐂

0 · Reply

Veraton Nov. 29 at 12:47 PM

$ELDN digest this The biggest hidden clue: Dr. Witkowski This is the smoking gun many retail traders ignore. Dr. Piotr Witkowski: Runs both Vertex’s islet transplant trials AND Eledon’s T1D transplantation trials. Is head of University of Chicago pancreas/islet program Is one of the most influential transplant specialists in the U.S. If one doctor is leading both programs, it means: Same clinical infrastructure Same immunosuppressive philosophy Same graft endpoints Same patient flow Same transplant criteria

1 · Reply

Sheajones Nov. 28 at 2:47 AM

$ELDN Happy Thanksgiving. I have always been puzzled by those who share their positivity late in the game when much has happened over the years. They swoop in and act like they know a thing or two but we all know, even a broken clock is right twice a day. They've been sharing their so called positive insights at much higher stock prices so the only ill timing, is with their own previous recommendations. Their desperation trying to create a story where there isnt one is obvious. These same used car salesman were touting ELDN at $20 a share, keep that in mind.

0 · Reply

red1 Nov. 27 at 10:06 PM

$ELDN $VRTX partnership for sure !

0 · Reply

Veraton Nov. 27 at 9:51 PM

$ELDN Its a matter of weeks, months....

0 · Reply

OnlyInvestor Nov. 27 at 9:40 PM

$ELDN or $SANA …. Or both? If SANA’s stem cell derived, protected beta cells fail to hide from the immune system, would ELDN’s tegoprubart help? If SANA is successful though, is there any application for tegoprubart??

1 · Reply

SeaSog Nov. 27 at 7:34 PM

$ELDN Happy Thanksgiving all. I have always been puzzled by a few who share their disgruntlement over ill timed investments. As with all stocks, it requires some degree of strategy as a retail investor knowing it's the big money that controls the stock price. On the side of wisdom - Eledon has something very special in the pipeline. It requires looking at the big picture. Even though the most recent Tegoprubart results crushed the existing drug, there was one deficiency out of eleven categories in the safety profile - which was proteinuria. The solution to that is a drug under FDA review called Povetacicept. Vertex owns that drug. Additionally, in the T1D arena, Vertex has developed a new approach to islet cell transplantation that requires a cutting edge immunosuppressant - which would be Tegoprubart - to make it all work. The common element in the T1D trials is Dr. Witkowski at U Chicago who is running the trials for Vertex and Eledon. Not selling anything - just facts.

1 · Reply

Sheajones Nov. 27 at 5:51 AM

$ELDN What happened little Eledon? Can't even hold onto $1.60 a share little bitch? Well, at least Eledon Executive Management and their investment bankers are making money with their stock warrants. Because that is what's most important.

0 · Reply

Sheajones Nov. 26 at 3:16 PM

$ELDN Beware of ignorant, used car salesman twats on here like Veraton trying to push this stock because he owns stock warrants. Look at the history of these hollow theories and recommendations when the stock price was much higher. He blocked me because I was calling him out on his BS. I am long ELDN but wouldn't wish this stock on anyone.

1 · Reply

Iightning Nov. 26 at 5:47 AM

1ightning® Options Trade Alert (Actionable) | Buy $ELDN Dec 19 $2 Call | Enter: $0.05 Exit: $0.06 | Profit: 25.82% ROI | https://1ightning.com

0 · Reply

Ontherag Nov. 26 at 4:32 AM

$ELDN Coastline Capital now on board at 5.98%. We should see more of these coming in soon. Good to see.

1 · Reply

red1 Nov. 25 at 9:58 PM

$ELDN sorry that was vertex.. This is the link to the 5 off insulin https://vt.tiktok.com/ZSfP6nVDn/

0 · Reply

red1 Nov. 25 at 9:36 PM

$ELDN https://vt.tiktok.com/ZSfP6FvLP/

0 · Reply

Market Cap	88.70M
Revenue (ttm)	0.00
Net Income (ttm)	-36.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,155,371
Avg Vol	2,542,072
Day's Range	N/A - N/A
Shares Out	59.93M
Stochastic %K	69%
Beta	0.79
Analysts	Strong Sell
Price Target	$8.00